Lv1
60 积分 2025-07-01 加入
WCN25-3301 Flozination in kidney transplant recipients: is it safe?
28天前
已关闭
Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Kidney Transplant Recipients with Chronic Kidney Disease with or without Diabetes
1个月前
已关闭
Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database
1个月前
已完结
GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events
3个月前
已完结
Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients
3个月前
已完结
Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
3个月前
已完结
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Kidney Transplantation: A Systematic Review and Meta-Analysis
3个月前
已关闭
Dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats
10个月前
已完结
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
10个月前
已完结
皖公网安备34019202002308
